Endoscopy Devices Market Size to Hit USD 105.90 Billion by 2035 | SNS Insider

The U.S. endoscopy devices market is forecast to grow from $24.61B in 2025 to $41.48B by 2035, while Europe is expected to rise from $17.72B to $29.44B. Growth is attributed to higher adoption of minimally invasive procedures, high-definition imaging systems, and disposable endoscopes.

Analysis

This is a slow-burn medtech TAM story, not an immediate earnings catalyst. The investable edge is in mix shift: suppliers with recurring disposables, imaging upgrades, and installed-base lock-in should compound faster than pure capital-equipment vendors, while price-sensitive hospitals push procurement toward opex-friendly single-use tools only if reimbursement and labor savings clearly offset the unit-cost premium.

The less obvious loser is the reprocessing/sterilization ecosystem: if single-use adoption inflects, volume can leak away from cleaning, repair, and refurbishment revenue even as procedure counts rise. That creates a second-order margin risk for vendors whose “endoscopy exposure” is really service-and-maintenance, not proprietary consumables.

Timing matters: over the next 1-3 months this is mostly noise unless an OEM issues color on disposable penetration or consumables mix. Over 6-18 months, the key catalyst path is FDA/CE approvals and hospital capex cycles; the thesis breaks if payors resist reimbursement or if clinicians keep reusable scopes the default because image quality and total cost of ownership stay superior.

Key Decisions for Investors

• Long BSX on pullbacks over the next 3-6 months; best risk/reward is exposure to recurring GI consumables and procedure growth rather than pure hardware. Thesis fails if endoscopy-related organic growth stalls or management does not show mix shift toward disposables.
• Watch-not-trade: STE as a potential short only if channel checks confirm single-use endoscope adoption is displacing reprocessing/repair volumes. Use as a relative-value hedge against pure consumables exposure; stop out if STE’s endoscopy/service revenue remains resilient.
• Long XHE as a basket way to own the multi-year endoscopy upgrade cycle, but size modestly because the article is too far out in time to justify a high-conviction catalyst trade. Prefer adding only after a weak tape or broad medtech de-rating.
• If an earnings season update shows disposable penetration accelerating, consider a BSX/STE pair trade for 1-3 month momentum capture. Cut the pair if reimbursement commentary turns negative or hospital purchasing delays appear.